Gastric Neuroendocrine Tumors Pipeline Insight 2019 - ResearchAndMarkets.com

DUBLIN--()--The "Gastric Neuroendocrine Tumors Pipeline Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Gastric Neuroendocrine Tumors (gNETs)- Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication.

A detailed picture of the Gastric Neuroendocrine Tumors pipeline landscape is provided which includes the disease overview and Gastric Neuroendocrine Tumors treatment guidelines. The assessment part of the report embraces, in depth Gastric Neuroendocrine Tumors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Neuroendocrine Tumors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Gastric Neuroendocrine Tumors (gNETs) Understanding

Gastric neuroendocrine tumors (gNETs) are neoplasms derived from the enterochromaffin-like cells (ECL cells) of the gastric mucosa. They are rare lesions with an indolent behavior and neuroendocrine differentiation. Although uncommon, their diagnosis is increasing, due to the widespread use of upper digestive endoscopy and the technical refinement of endoscopists. GNETs are classified into four types, based on pathogenesis and histomorphologic characteristics; these types differ in biological behavior and prognosis, ranging from benign to highly malignant biological behavior and extremely poor prognosis. Type I and II gastric NETs develop due to hypergastrinemia and ECL cell hyperplasia, while type III gastric NETs arise sporadically.

Gastric Neuroendocrine Tumors (gNETs) Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Gastric Neuroendocrine Tumors targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Gastric Neuroendocrine Tumors pipeline report covers 6+ companies. Some of the key players include Ipsen (Satoreotide trizoxetan) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Gastric Neuroendocrine Tumors (gNETs) Analytical Perspective

In-depth Gastric Neuroendocrine Tumors Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Gastric Neuroendocrine Tumors Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

  • The Gastric Neuroendocrine Tumors report provides an overview of therapeutic pipeline activity for Gastric Neuroendocrine Tumors across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Gastric Neuroendocrine Tumors therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Gastric Neuroendocrine Tumors Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Gastric Neuroendocrine Tumors

Key Topics Covered:

1. Report Introduction

2. Gastric Neuroendocrine Tumors (gNETs)

2.1. Gastric Neuroendocrine Tumors (gNETs) Disease Overview

2.2. Gastric Neuroendocrine Tumors (gNETs) History

2.3. Gastric Neuroendocrine Tumors (gNETs) Symptoms

2.4. Gastric Neuroendocrine Tumors (gNETs) Causes

2.5. Gastric Neuroendocrine Tumors (gNETs) Pathophysiology

2.6. Gastric Neuroendocrine Tumors (gNETs) Diagnosis

2.6.1. Diagnostic Guidelines

3. Gastric Neuroendocrine Tumors Current Treatment Patterns

3.1. Treatment Guidelines

4. Gastric Neuroendocrine Tumors - Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Gastric Neuroendocrine Tumors companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Gastric Neuroendocrine Tumors Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis

4.1.2.2. Gastric Neuroendocrine Tumors Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono/Combination)

4.2.2.1. Assessment by Stage and Product Type

4.2.3. Assessment by Route of Administration

4.2.3.1. Assessment by Stage and Route of Administration

4.2.4. Assessment by Molecule Type

4.2.4.1. Assessment by Stage and Molecule Type

4.2.5. Assessment by MOA

4.2.5.1. Assessment by Stage and MOA

5. Gastric Neuroendocrine Tumors Pipeline Therapeutics

5.1. Late Stage Products (Phase-III)

5.1.1. Comparative Analysis

5.2. Mid Stage Products (Phase-II)

5.2.1. Comparative Analysis

5.3. Early Stage Products (Phase-I)

5.3.1. Comparative Analysis

5.4. Pre-clinical and Discovery Stage Products

5.4.1. Comparative Analysis

5.5. Inactive Products

6. Gastric Neuroendocrine Tumors -Products Analysis

6.1. Product Profiles

6.1.1. Ipsen (Satoreotide trizoxetan)

6.1.1.1. Product Description

6.1.1.1.1. Product Overview

6.1.1.1.2. Mechanism of Action

6.1.1.2. Research and Development

6.1.1.2.1. Clinical Studies

6.1.1.2.1.1. Detailed Study Description

6.1.1.2.1.2. Study Results

6.1.1.2.1.3. Clinical Trials: Tabular View

6.1.1.3. Product Development Activities

6.1.1.3.1. Tabulated Product Summary

6.1.1.3.1.1. General Description Table

7. Recent Technologies

8. Gastric Neuroendocrine Tumors Key Companies

8.1. Tarveda Therapeutics

8.2. Ipsen

8.3. Pfizer

8.4. Xencor

8.5. Trio Medicines

8.6. Taiho Pharmaceutical

9. Gastric Neuroendocrine Tumors Key Products

9.1. PEN 221

9.2. Satoreotide trizoxetan

9.3. Sunitinib

9.4. Tidutamab

9.5. Ceclazepide

9.6. Netazepide

9.7. Tipiracil/trifluridine

10. Dormant and Discontinued Products

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. Gastric Neuroendocrine Tumors - Unmet Needs

12. Gastric Neuroendocrine Tumors - Future Perspectives

13. Appendix

Companies Mentioned

  • Tarveda Therapeutics
  • Ipsen
  • Pfizer
  • Xencor
  • Trio Medicines
  • Taiho Pharmaceutical
  • Advanced Accelerator Applications

For more information about this report visit https://www.researchandmarkets.com/r/r5cryq

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900